Research programme: protein therapeutics - AffibodyAlternative Names: CAIX - Affibody; HER3 - Affibody
Latest Information Update: 23 Apr 2012
At a glance
- Originator Affibody
- Class Proteins
- Mechanism of Action Carbonic anhydrase inhibitors; ERBB-3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Breast cancer; Cancer
Most Recent Events
- 23 Apr 2012 Research is ongoing in Sweden
- 12 Oct 2005 Early research in Breast cancer in Sweden (SC)